Free Trial

Eton Pharmaceuticals (ETON) News Today

Eton Pharmaceuticals logo
$16.97 -0.37 (-2.13%)
Closing price 05/5/2025 04:00 PM Eastern
Extended Trading
$17.00 +0.04 (+0.21%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Marshall Wace LLP
Marshall Wace LLP grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 75.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 36,182 shares of the company's stock after purchasing an addition
Eton Pharmaceuticals, Inc. stock logo
683 Capital Management LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
683 Capital Management LLC acquired a new position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 69,000 shares of the company's st
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals (ETON) to Release Quarterly Earnings on Thursday
Eton Pharmaceuticals (NASDAQ:ETON) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-eton-pharmaceuticals-inc-stock/)
Eton Pharmaceuticals, Inc. stock logo
Q1 EPS Estimate for Eton Pharmaceuticals Lifted by Analyst
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities research analysts at B. Riley lifted their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research note issued on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will earn $0.13 per share for
Eton Pharmaceuticals, Inc. stock logo
JPMorgan Chase & Co. Acquires 51,238 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
JPMorgan Chase & Co. raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 7,086.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 51,961 shares of the company's stock after buying an add
Eton Pharmaceuticals, Inc. stock logo
B. Riley Lifts Earnings Estimates for Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley upped their Q4 2025 earnings per share estimates for Eton Pharmaceuticals in a report released on Sunday, April 27th. B. Riley analyst M. El-Saadi now forecasts that the company will post earnings of $0.33 p
Eton Pharmaceuticals, Inc. stock logo
Nantahala Capital Management LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
Nantahala Capital Management LLC boosted its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 12.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,118,483 shares of the company's stock after acquiring an additional 119,750 shares during t
Eton Pharmaceuticals, Inc. stock logo
24,710 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Bought by Jump Financial LLC
Jump Financial LLC acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 24,710 shares of the company's stock, valued at approximately $329,000.
Eton Pharmaceuticals, Inc. stock logo
Renaissance Technologies LLC Has $2.57 Million Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
Renaissance Technologies LLC grew its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 131.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 193,100 shares of the company's stock after b
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Update
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 343,900 shares, a growth of 46.0% from the March 15th total of 235,600 shares. Based on an average trading volume of 287,400 shares, the short-interest ratio is presently 1.2 days. Currently, 1.6% of the company's shares are short sold.
Eton Pharmaceuticals, Inc. stock logo
EAM Investors LLC Decreases Stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
EAM Investors LLC trimmed its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 95,019 shares of the company's stock after selling 33,257 shares during the period
B.Riley Financial Remains a Buy on Eton Pharmaceuticals (ETON)
Eton Pharmaceuticals management to meet virtually with B. Riley
Eton Pharmaceuticals management to meet with Craig Hallum
Eton Pharmaceuticals, Inc. stock logo
Cannell Capital LLC Purchases New Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
Cannell Capital LLC bought a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 381,323 shares of the company's stock, valued at approximately
Eton Pharmaceuticals, Inc. stock logo
Aristides Capital LLC Grows Stock Holdings in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
Aristides Capital LLC raised its stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 20.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 241,587 shares of the company's stoc
Eton Pharmaceuticals out-licenses international rights to Increlex
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Sees Significant Drop in Short Interest
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 235,600 shares, a decline of 18.6% from the February 28th total of 289,400 shares. Based on an average daily volume of 278,300 shares, the days-to-cover ratio is presently 0.8 days. Currently, 1.1% of the company's stock are sold short.
Eton Pharmaceuticals, Inc. stock logo
Hillsdale Investment Management Inc. Invests $226,000 in Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
Hillsdale Investment Management Inc. acquired a new stake in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 17,003 shares of the company's stock, valued
Eton Pharmaceuticals, Inc. stock logo
B. Riley Equities Analysts Raise Earnings Estimates for ETON
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley increased their Q3 2025 earnings estimates for Eton Pharmaceuticals in a note issued to investors on Wednesday, March 19th. B. Riley analyst M. El-Saadi now anticipates that the company will post earnings pe
Eton Pharmaceuticals, Inc. stock logo
Q2 EPS Estimate for Eton Pharmaceuticals Lowered by Analyst
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Stock analysts at HC Wainwright cut their Q2 2025 earnings estimates for shares of Eton Pharmaceuticals in a research note issued to investors on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now anticipates that the company wil
Eton Pharmaceuticals, Inc. stock logo
Q1 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) - Equities researchers at B. Riley increased their Q1 2025 EPS estimates for Eton Pharmaceuticals in a report issued on Wednesday, March 19th. B. Riley analyst M. El-Saadi now expects that the company will post earnings of $0.06 per share for
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says
Craig Hallum raised their price objective on shares of Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday.
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals' (ETON) "Buy" Rating Reiterated at B. Riley
B. Riley restated a "buy" rating and set a $24.00 price target (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday.
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals (NASDAQ:ETON) Given Buy Rating at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday.
Eton Pharmaceuticals price target raised to $24 from $21 at B. Riley
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 18.0% in February
Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 289,400 shares, a decrease of 18.0% from the February 13th total of 353,000 shares. Based on an average daily trading volume, of 263,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 1.3% of the company's shares are short sold.
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals (NASDAQ:ETON) Announces Quarterly Earnings Results
Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.02). Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%.
Eton Pharmaceuticals reports Q4 EPS (2c), consensus 0c
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.
Connor Clark & Lunn Investment Management Ltd. grew its position in Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 230.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 214,878 shares of the com
Eton Pharmaceuticals reports ‘positive’ data from study of ET-600
Eton Pharmaceuticals, Inc. stock logo
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday
Eton Pharmaceuticals (NASDAQ:ETON) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports.
Get Eton Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.

ETON Media Mentions By Week

ETON Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ETON
News Sentiment

0.90

0.72

Average
Medical
News Sentiment

ETON News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ETON Articles
This Week

16

3

ETON Articles
Average Week

Get Eton Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ETON) was last updated on 5/6/2025 by MarketBeat.com Staff
From Our Partners